Copy Link Print Information

Vudalimab

(Synonyms: XMAB-20717)
Kundenbewertung

Based on 1 Customer Validation

Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: ≥99.0%
  • CAS. Nr.: 2329669-72-7
  • Molecular Weight:144.5 kDa
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Vudalimab
  • Experimental Validation Results for Vudalimab
  • Experimental Validation Results for Vudalimab
  • Vudalimab Chemical Structure
    Vudalimab Chemical Structure
CAS. Nr.: 2329669-72-7
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Vudalimab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3

  • 1/16

    Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Vudalimab (anti-CTLA4) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Vudalimab (anti-PDCD1) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Vudalimab Chemical Structure
    1/16
  • Vudalimab
  • Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Vudalimab (anti-CTLA4) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Vudalimab (anti-PDCD1) (HY-P99166). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3